Stockscreener 앱 받기
3.88
2.92%
0.11
전일 마감가:
$3.77
열려 있는:
$3.76
하루 거래량:
1.78M
Relative Volume:
0.50
시가총액:
$657.41M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-194.00
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+0.00%
1개월 성능:
+7.33%
6개월 성능:
+90.20%
1년 성능:
+347.78%
1일 변동 폭
$3.725
$3.94
1주일 범위
$3.42
$3.94
52주 변동 폭
$0.40
$4.62
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.88 | 638.77M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike - Yahoo Finance
Will CytomX Therapeutics Inc. stock deliver consistent dividendsTrade Entry Report & Expert Curated Trade Setup Alerts - newser.com
Will CytomX Therapeutics Inc. stock see insider buyingEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Why CytomX Therapeutics Inc. (6C1) stock gets analyst attentionExit Point & High Accuracy Buy Signal Tips - newser.com
CytomX at Jefferies Conference: Promising Cancer Treatment Insights By Investing.com - Investing.com Canada
Is CytomX Therapeutics Inc. stock a bargain at current levelsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
What technical charts say about CytomX Therapeutics Inc. stockJuly 2025 Fed Impact & Free Verified High Yield Trade Plans - newser.com
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionGap Up & Weekly Setup with High ROI Potential - newser.com
How CytomX Therapeutics Inc. (6C1) stock behaves in tightening cyclesRecession Risk & Low Drawdown Investment Ideas - newser.com
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy call2025 Retail Activity & Verified Entry Point Signals - newser.com
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow JonesMarket Sentiment Report & Weekly Setup with High ROI Potential - newser.com
Can CytomX Therapeutics Inc. stock beat analyst upgrades2025 Market Overview & Weekly High Potential Stock Alerts - newser.com
Is CytomX Therapeutics Inc. (6C1) stock included in top ETFsWeekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
CytomX Therapeutics: Leaning Into The Hype, But What's Next? (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics (CTMX) Price Target Increased by 15.12% to 7.21 - Nasdaq
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stock2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Why retail traders accumulate CytomX Therapeutics Inc. (6C1) stock2025 Biggest Moves & Community Consensus Picks - newser.com
How to integrate CytomX Therapeutics Inc. into portfolio analysis tools2025 Performance Recap & Weekly High Momentum Picks - newser.com
What drives CytomX Therapeutics Inc 6C1 stock priceVolume Profile Analysis & Best Stocks For Explosive Growth - earlytimes.in
Will CytomX Therapeutics Inc. stock reach Wall Street targets2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):